GH Secretagogues Drug-Drug Interaction Table

How GH Secretagogues Work and Why DDIs Matter

GH secretagogues stimulate pulsatile growth hormone release through two receptor systems: the growth hormone releasing hormone receptor (GHRH-R) and the growth hormone secretagogue receptor (GHS-R1a, the ghrelin receptor). GHRH analogs like sermorelin, tesamorelin, and CJC-1295 act on GHRH-R. Ghrelin mimetics like ipamorelin and MK-677 act on GHS-R1a 1.

Pulsatile GH Release and the Feedback Loop

The hypothalamic-pituitary axis regulates GH through opposing GHRH and somatostatin signals. Exogenous secretagogues amplify the GHRH arm of this cycle, producing supraphysiologic GH pulses that raise IGF-1 levels over days to weeks 2. Any co-administered drug that alters somatostatin tone, glucose metabolism, or hepatic CYP activity can shift the pharmacodynamic or pharmacokinetic profile of these agents.

Why This Class Has Unique DDI Concerns

Unlike exogenous recombinant GH (somatropin), secretagogues preserve feedback inhibition, meaning co-prescribed drugs that alter feedback sensitivity produce unpredictable GH output. Somatostatin analogs directly oppose the mechanism. Glucocorticoids blunt GH secretion centrally while GH itself antagonizes cortisol's metabolic effects 3. The oral ghrelin mimetic MK-677 adds hepatic metabolism concerns absent from injectable peptides.

Somatostatin Analogs: Pharmacologic Antagonism

Octreotide, lanreotide, and pasireotide directly activate somatostatin receptors SST2 and SST5, suppressing GH release at the pituitary. Co-administration with any GH secretagogue produces near-complete pharmacologic antagonism 4.

Clinical Consequence

A patient receiving octreotide LAR 20 mg monthly for acromegaly or a neuroendocrine tumor will have profoundly suppressed GH response to ipamorelin or CJC-1295. The interaction is bidirectional: the secretagogue partially overcomes somatostatin suppression in an unpredictable, dose-dependent fashion, destabilizing tumor or acromegaly control.

Management

This combination is contraindicated. If a patient on somatostatin analog therapy requires GH augmentation for a separate indication, direct recombinant GH (somatropin) with endocrinology co-management is the appropriate pathway, not a secretagogue 5.

Insulin and Oral Hypoglycemics: Glucose Axis Interactions

GH is a counter-regulatory hormone. Secretagogue-induced GH pulses reduce peripheral glucose uptake and increase hepatic glucose output. The FDA-approved tesamorelin label documents fasting glucose increases of 3-5 mg/dL in HIV lipodystrophy trials, with new-onset diabetes in 4.4% of tesamorelin-treated patients versus 1.3% on placebo over 26 weeks 6.

Insulin Dose Adjustments

Patients on basal insulin (glargine, degludec) may require 10-20% dose increases within 4-6 weeks of secretagogue initiation. Rapid-acting insulin users face a higher risk of postprandial hyperglycemia because GH-mediated lipolysis increases free fatty acid flux, worsening hepatic insulin resistance 7.

Metformin and SGLT2 Inhibitors

Metformin's hepatic glucose suppression partially offsets GH-driven gluconeogenesis. This pairing is generally manageable. SGLT2 inhibitors (empagliflozin, dapagliflozin) carry a theoretical concern: GH-mediated lipolysis combined with SGLT2-driven glycosuria may increase ketogenesis risk in susceptible patients, particularly those with low carbohydrate intake or type 1 diabetes 8.

Sulfonylureas and GLP-1 Receptor Agonists

Sulfonylureas (glimepiride, glipizide) operate through insulin secretion that does not counteract GH-driven insulin resistance at the peripheral level. Monitor fasting glucose at 2-week intervals for the first 8 weeks. GLP-1 receptor agonists (semaglutide, tirzepatide) slow gastric emptying, which is additive with MK-677's ghrelin-mediated gastric motility effects. Nausea incidence may increase 9.

Glucocorticoids: Bidirectional Suppression

Exogenous glucocorticoids suppress GH secretion at the hypothalamic level while simultaneously reducing hepatic IGF-1 production. Prednisone doses above 7.5 mg/day can reduce secretagogue efficacy by 40-60% based on GH stimulation testing data 10.

Short-Course Steroids

A 5-7 day methylprednisolone taper for an acute condition is unlikely to meaningfully blunt secretagogue response. No dose adjustment is needed for short courses.

Chronic Glucocorticoid Use

Patients on chronic prednisone (≥5 mg/day for >3 months) will have suppressed hypothalamic-pituitary GH reserve. Secretagogue efficacy is reduced. IGF-1 response should be measured at 6 weeks; if IGF-1 fails to rise above baseline by ≥30%, the secretagogue is unlikely to deliver clinical benefit in the setting of ongoing glucocorticoid exposure 11.

Inhaled Corticosteroids

High-dose inhaled fluticasone (>1,000 mcg/day) produces measurable systemic cortisol suppression and may partially attenuate GH secretagogue response. Standard-dose ICS (<500 mcg/day fluticasone equivalent) does not require monitoring adjustments 12.

MK-677 (Ibutamoren): CYP3A4 Metabolism Interactions

MK-677 is the only widely used oral GH secretagogue. It undergoes hepatic metabolism primarily through CYP3A4 13.

Strong CYP3A4 Inhibitors

Ketoconazole, itraconazole, clarithromycin, ritonavir, and cobicistat increase MK-677 exposure. The degree of AUC increase has not been formally quantified in published interaction studies, but extrapolation from CYP3A4-substrate class pharmacology predicts 2-4 fold exposure increases with strong inhibitors. Reduce MK-677 dose by 50% or hold during strong CYP3A4 inhibitor courses 13.

Strong CYP3A4 Inducers

Rifampin, phenytoin, carbamazepine, and St. John's wort accelerate MK-677 clearance and may render standard doses subtherapeutic. Consider dose increases with IGF-1-guided titration or switch to an injectable secretagogue that bypasses hepatic metabolism.

Injectable Secretagogues and CYP Interactions

Ipamorelin, CJC-1295, sermorelin, and tesamorelin are peptides cleared by proteolysis, not hepatic CYP enzymes. They have no known CYP-mediated drug interactions. This is a clinically relevant distinction when choosing within the class for patients on complex medication regimens 14.

Thyroid Hormone Interactions

GH increases peripheral conversion of T4 to T3 by upregulating type 1 deiodinase activity. Patients on levothyroxine for hypothyroidism may develop relative T4 depletion with elevated T3 levels after secretagogue initiation. The Endocrine Society's 2011 GH treatment guidelines recommend checking free T4 and TSH at 6-8 weeks after starting GH-augmenting therapy 15.

Practical Monitoring

Recheck thyroid panel (TSH, free T4, free T3) at baseline and at 6-8 weeks. If free T4 drops below the reference range with normal TSH, increase levothyroxine by 12.5-25 mcg. Patients already on combination T4/T3 therapy require T3-level monitoring to avoid supratherapeutic T3 concentrations.

Anticoagulants and Antiplatelets

GH secretagogues do not directly alter coagulation pathways. No INR changes with warfarin have been reported. The interaction concern is indirect: GH-mediated fluid retention can alter warfarin distribution volume in patients with borderline hepatic function. An INR check at 4 weeks after secretagogue initiation is reasonable in warfarin-treated patients 16.

Direct oral anticoagulants (DOACs) like apixaban and rivarelbaan are CYP3A4 substrates. Co-administration of MK-677 is unlikely to produce clinically meaningful interactions because MK-677 is a CYP3A4 substrate, not an inhibitor or inducer. No dose adjustment is required for DOACs with injectable GH secretagogues.

Drugs That Raise Prolactin

Some GH secretagogues (hexarelin, GHRP-6) produce dose-dependent prolactin elevations. Ipamorelin is notable for minimal prolactin stimulation. Co-administration of prolactin-raising drugs (antipsychotics such as risperidone and haloperidol, metoclopramide, domperidone) with hexarelin or GHRP-6 may produce additive hyperprolactinemia 17.

Clinical Approach

If a secretagogue is needed in a patient on an antipsychotic, ipamorelin is the preferred agent due to its receptor selectivity (GHS-R1a without significant prolactin or cortisol stimulation). Monitor prolactin at baseline and 8 weeks regardless of agent selection.

Comprehensive DDI Reference Table

| Interacting Drug/Class | Secretagogue(s) Affected | Mechanism | Severity | Management | |---|---|---|---|---| | Octreotide, lanreotide, pasireotide | All | Pharmacologic antagonism at SST2/SST5 | Contraindicated | Do not combine | | Insulin (basal and bolus) | All | GH opposes peripheral glucose uptake | Moderate | Monitor FBG; expect 10-20% insulin dose increase | | Sulfonylureas | All | Inadequate offset of GH-driven insulin resistance | Moderate | FBG checks every 2 weeks for 8 weeks | | SGLT2 inhibitors | All | Additive ketogenesis risk (GH lipolysis + glycosuria) | Moderate | Monitor ketones in high-risk patients | | GLP-1 receptor agonists | MK-677 | Additive GI effects (gastric motility) | Low-Moderate | Counsel on nausea; stagger dosing | | Prednisone ≥7.5 mg/day | All | Central GH suppression + reduced IGF-1 synthesis | Moderate | Check IGF-1 at 6 weeks; consider futility | | Ketoconazole, itraconazole | MK-677 | CYP3A4 inhibition, increased MK-677 AUC | Moderate-High | Reduce MK-677 dose 50% or hold | | Clarithromycin, erythromycin | MK-677 | CYP3A4 inhibition | Moderate | Short courses: hold MK-677 during treatment | | Ritonavir, cobicistat | MK-677 | Strong CYP3A4 inhibition | High | Avoid MK-677; use injectable secretagogue | | Rifampin, phenytoin, carbamazepine | MK-677 | CYP3A4 induction, reduced MK-677 exposure | Moderate | Titrate by IGF-1 or switch to injectable | | Levothyroxine | All | GH upregulates T4-to-T3 conversion | Low-Moderate | Recheck free T4 at 6-8 weeks | | Warfarin | All (theoretical) | GH fluid retention alters Vd | Low | INR check at 4 weeks | | Antipsychotics (risperidone, haloperidol) | Hexarelin, GHRP-6 | Additive prolactin elevation | Moderate | Prefer ipamorelin; check prolactin at 8 weeks | | Metoclopramide, domperidone | Hexarelin, GHRP-6 | Additive prolactin elevation | Low-Moderate | Prefer ipamorelin if long-term use |

Monitoring Protocol After Secretagogue Initiation

The American Association of Clinical Endocrinologists (AACE) 2019 growth hormone guidelines recommend structured laboratory monitoring for all GH-augmenting therapies 18.

Baseline Labs

Before starting any GH secretagogue, obtain: fasting glucose, HbA1c, IGF-1, complete metabolic panel, TSH with free T4, prolactin (if using hexarelin or GHRP-6), and lipid panel.

Follow-Up Schedule

At 4-6 weeks: fasting glucose, IGF-1. At 8-12 weeks: fasting glucose, IGF-1, HbA1c, TSH with free T4. Quarterly thereafter: fasting glucose, IGF-1. Annual: HbA1c, lipid panel, TSH with free T4.

When to Stop

Discontinue the secretagogue if IGF-1 exceeds 1.5x the age-adjusted upper limit of normal on two consecutive draws, if HbA1c rises >0.5% from baseline without another cause, or if the patient develops new-onset diabetes. The Endocrine Society recommends IGF-1 normalization as the primary safety target for all GH-augmenting therapies 15.